Physician profile
Michael E Froniewski
NPI 1093287161
$12,716.28
in general payments reported to CMS, 2019-2025
27 companies · $3,127 in 2025
The $3,127 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $375 · 2022: $1,405 · 2023: $4,290 · 2024: $3,519 · 2025: $3,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,564.88 |
| Education | $370.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,816.32 | 2021-2025 | |
| Janssen Biotech, INC. | $1,464.46 | 2021-2025 | Tremfya, Simponi Aria |
| Incyte Corporation | $1,074.10 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $1,070.59 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $1,064.18 | 2023-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $849.71 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $794.01 | 2021-2025 | |
| Leo Pharma INC. | $690.96 | 2023-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $683.46 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $559.78 | 2023-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $524.75 | 2021-2025 | Ilumya |
| Janssen Scientific Affairs, LLC | $442.26 | 2022 | |
| Amgen INC. | $416.01 | 2022-2025 | Otezla |
| Pfizer INC. | $340.88 | 2023-2025 | |
| Galderma Laboratories, L.P. | $172.31 | 2023-2025 | Nemluvio, Aklief |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $145.11 | 2022-2025 | Cimzia, Bimzelx |
| Allergan, INC. | $130.38 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.31 | 2023 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $90.66 | 2023-2025 | Jublia, Cabtreo |
| Revance Therapeutics, INC. | $64.30 | 2025 | Daxxify |
| Organon LLC | $45.47 | 2025 | Vtama |
| Dermavant Sciences, INC. | $42.28 | 2024 | Vtama |
| Botanix Sb INC | $35.95 | 2025 | Sofdra |
| Almirall LLC | $25.48 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $19.53 | 2023 | Ycanth |
| Strata Skin Sciences, INC. | $19.05 | 2023 | Xtrac |
| Vyne Pharmaceuticals INC. | $11.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Froniewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.